Syndax Pharmaceuticals, Inc.

Healthcare · Biotechnology · United States

Last price 14.15 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.26B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination...